CRTX Cortexyme, Inc. Stock Quote

CRTX [NASD]

Index	-	P/E	-	EPS (ttm)	-2.81	Insider Own	1.30%	Shs Outstand	29.55M	Perf Week	19.91%
Market Cap	1.91B	Forward P/E	-	EPS next Y	-3.83	Insider Trans	-17.42%	Shs Float	19.77M	Perf Month	12.41%
Income	-82.80M	PEG	-	EPS next Q	-0.76	Inst Own	63.00%	Short Float	15.42%	Perf Quarter	67.80%
Sales	-	P/S	-	EPS this Y	-35.60%	Inst Trans	0.05%	Short Ratio	15.32	Perf Half Y	100.00%
Book/sh	5.29	P/B	12.14	EPS next Y	-25.60%	ROA	-42.00%	Target Price	73.86	Perf Year	48.65%
Cash/sh	4.95	P/C	12.98	EPS next 5Y	18.30%	ROE	-45.80%	52W Range	26.66 - 65.70	Perf YTD	131.10%
Dividend	-	P/FCF	-	EPS past 5Y	-	ROI	-	52W High	-2.28%	Beta	-
Dividend %	-	Quick Ratio	8.40	Sales past 5Y	-	Gross Margin	-	52W Low	140.80%	ATR	3.95
Employees	37	Current Ratio	8.40	Sales Q/Q	-	Oper. Margin	-	RSI (14)	67.41	Volatility	8.19% 6.89%
Optionable	Yes	Debt/Eq	0.00	EPS Q/Q	-28.50%	Profit Margin	-	Rel Volume	0.80	Prev Close	64.49
Shortable	Yes	LT Debt/Eq	0.00	Earnings	-	Payout	-	Avg Volume	198.89K	Price	64.20
Recom	2.70	SMA20	13.88%	SMA50	30.25%	SMA200	53.38%	Volume	158,641	Change	-0.45%

Apr-26-21

Resumed

Credit Suisse

Underperform

$14

Feb-17-21

Downgrade

Jefferies

Buy → Hold

$59 → $34

Dec-11-20

Initiated

Citigroup

Sell

$20

Jun-24-20

Initiated

H.C. Wainwright

Buy

$76

Jun-02-20

Initiated

Jefferies

Buy

$59

Jun-03-19

Initiated

JMP Securities

Mkt Outperform

$53

Jun-03-19

Initiated

Credit Suisse

Underperform

$14

Jun-03-19

Initiated

Canaccord Genuity

Buy

$42

Jun-03-19

Initiated

BofA/Merrill

Neutral

$28

Jul-23-21 08:00AM	Cortexyme Announces Lead 3CLpro Inhibitor for the Treatment of Coronavirus Infection Business Wire
Jul-22-21 08:00AM	Cortexyme to Present New Data at AAIC 2021 Business Wire +5.41%
Jul-21-21 08:00AM	Cortexyme Presents New Data Demonstrating Atuzaginstat Disrupts Biofilms and is Efficacious in Preclinical Models of Periodontal Disease at IADR 2021 Business Wire +5.92%
Jul-19-21 08:00AM	Cortexyme to Host Symposium at AAIC 2021 Business Wire
Jul-08-21 08:00AM	Cortexyme to Host Two-Part Key Opinion Leader Webinar Series on Atuzaginstat Business Wire +5.08%
Jun-13-21 02:20PM	Hedge Funds Are Dumping Cortexyme, Inc. (CRTX) Insider Monkey
Jun-01-21 08:00AM	Cortexyme Presents Updated Baseline Data from Complete Set of Participants Enrolled in Pivotal GAIN Trial at ASCP 2021 Annual Meeting Business Wire
May-26-21 08:00AM	Cortexyme to Present at Investor Conferences in June 2021 Business Wire +12.99%
May-10-21 08:00AM	Cortexyme Provides Business Update and Reports First Quarter 2021 Results Business Wire -9.81%
May-09-21 04:13AM	How Much Are Cortexyme, Inc. (NASDAQ:CRTX) Insiders Spending On Buying Shares? Simply Wall St.
May-04-21 08:00AM	Cortexyme to Present at the BofA Securities 2021 Healthcare Conference on May 11, 2021 Business Wire -7.96%
Mar-25-21 08:00AM	Cortexyme to Present at the Stifel 3rd Annual CNS Day on April 1, 2021 Business Wire
Mar-21-21 09:52PM	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cortexyme, Inc. - CRTX Newsfile
Mar-18-21 08:01PM	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cortexyme, Inc. - CRTX PR Newswire -5.33%
Mar-16-21 10:00PM	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cortexyme, Inc. - CRTX ACCESSWIRE
Mar-12-21 06:15AM	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cortexyme, Inc. - CRTX PR Newswire
Mar-10-21 08:00AM	Cortexyme to Present at the Oppenheimer 31st Annual Healthcare Conference on March 16, 2021 Business Wire +7.29%
Mar-09-21 10:45PM	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cortexyme, Inc. - CRTX ACCESSWIRE +9.07%
Mar-08-21 08:00AM	Cortexyme Announces Partnership with Parkinson Study Group and Upcoming Alzheimers Disease Data Presentation Business Wire
Mar-07-21 05:53PM	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cortexyme, Inc. - CRTX Newsfile
Mar-03-21 03:00AM	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cortexyme, Inc. - CRTX PR Newswire
Feb-22-21 01:10PM	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cortexyme, Inc. - CRTX Newsfile
Feb-20-21 07:00PM	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cortexyme, Inc. - CRTX ACCESSWIRE
Feb-18-21 09:47PM	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cortexyme, Inc. - CRTX PR Newswire
04:45PM	Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Cortexyme, Inc. (CRTX) Investigation ACCESSWIRE
Feb-17-21 11:38AM	The Bottom Is in for These 2 Stocks? Analysts Say Buy TipRanks
Feb-16-21 08:52AM	Cortexyme Stops Enrollment In Mid-Stage Atuzaginstat Study In Alzheimer's Disease Benzinga -35.29%
Feb-15-21 09:13PM	Cortexyme Provides Regulatory Update on Development Program for Atuzaginstat in Alzheimers Disease Business Wire
Feb-10-21 04:06PM	Cortexyme Announces Leadership Appointments to Support Advancement of Atuzaginstat and Pipeline Expansion Business Wire +6.75%
Feb-08-21 08:22AM	What to Know Before Buying Cassava Sciences, the Hot Alzheimers Stock Barrons.com
12:26AM	We're Not Very Worried About Cortexyme's (NASDAQ:CRTX) Cash Burn Rate Simply Wall St.
Feb-02-21 07:32PM	2 Biotech Stocks That Could Double in 2021; Canaccord Says Buy TipRanks
Jan-26-21 08:00AM	Cortexyme Announces Pipeline Update and Anticipated 2021 Milestones Business Wire +18.00%
Jan-06-21 08:49AM	Is the Options Market Predicting a Spike in Cortexyme (CRTX) Stock? Zacks
Dec-07-20 12:49AM	Is Cortexyme (CRTX) A Good Stock To Buy Now? Insider Monkey
Dec-04-20 07:43AM	The Daily Biotech Pulse: BioCryst's Heredity Angioedema Treatment Clears FDA, Sutro Biopharma Readout, 2 IPOs Benzinga -19.62%
07:00AM	Cortexymes Phase 2/3 GAIN Trial of Atuzaginstat (COR388) in Patients with Alzheimers Disease Successfully Advances Past Interim Analysis Business Wire
Dec-01-20 08:40AM	Is the Options Market Predicting a Spike in Cortexyme (CRTX) Stock? Zacks
Nov-27-20 10:27AM	New Strong Sell Stocks for November 27th Zacks
Nov-20-20 10:45AM	New Strong Sell Stocks for November 20th Zacks
Nov-12-20 04:30PM	Cortexyme Announces Third Quarter 2020 Financial Results and Provides Business Update Business Wire
Nov-10-20 07:12AM	Are Insiders Buying Cortexyme, Inc. (NASDAQ:CRTX) Stock? Simply Wall St.
Nov-05-20 08:00AM	Cortexyme Presents an Update and Baseline Data from the Phase 2/3 GAIN Trial of Atuzaginstat at CTAD 2020, the Clinical Trials on Alzheimers Disease Conference Business Wire +5.69%
Oct-19-20 08:00AM	Cortexyme Announces Upcoming Data Presentations at November 2020 Conferences Business Wire
Sep-24-20 08:00AM	Cortexyme Announces GAIN Trial of Atuzaginstat in Alzheimers Disease Has Exceeded Study Enrollment Target of 570 Patients Business Wire
Sep-09-20 08:00AM	Cortexyme to Present at the H.C. Wainwright 22nd Annual Global Investment Conference on September 14, 2020 Business Wire +6.28%
Aug-27-20 08:00AM	Cortexyme Announces Issuance of Composition of Matter Patent for Atuzaginstat by the U.S. Patent and Trademark Office Business Wire
Aug-18-20 09:21AM	Company News for Aug 18, 2020 Zacks
Aug-17-20 08:00AM	Cortexyme Announces Second Quarter 2020 Financial Results and Provides Business Update Business Wire
Aug-14-20 08:00AM	Cortexyme Announces GAIN Trial of Atuzaginstat in Alzheimers Disease Has Reached Enrollment Milestone of 500 Patients Business Wire
Aug-12-20 08:11AM	We're Hopeful That Cortexyme (NASDAQ:CRTX) Will Use Its Cash Wisely Simply Wall St.
08:10AM	Here's Why We're Not Too Worried About Cortexyme's (NASDAQ:CRTX) Cash Burn Situation Simply Wall St.
Aug-06-20 04:05PM	Cortexyme Announces Webcasts of Investor Conference Presentations in August 2020 Business Wire
Jul-29-20 08:00AM	Cortexyme to Participate in Virtual Fireside Chat Hosted by LifeSci Capital on July 30, 2020 Business Wire
Jul-28-20 06:09PM	Cortexyme Presents Data Linking P. gingivalis Infection to Cardiovascular Disease Severity and Alzheimer's Disease, Along With Evidence That Treatment With Atuzaginstat (COR388) Improves Biomarkers Associated With Both Diseases Business Wire
Jul-22-20 08:00AM	Cortexyme Announces Upcoming Data Presentations at the Alzheimers Association International Conference 2020 Business Wire
Jun-14-20 07:00AM	4 Biotech Stocks That Are Seeing Big Buys in June Barrons.com
Jun-12-20 04:27PM	Hedge Funds Are Buying Cortexyme, Inc. (CRTX) Insider Monkey
Jun-09-20 08:00AM	Cortexyme Announces "Atuzaginstat" Selected as First-in-Class Nonproprietary Name for COR388 Business Wire +11.12%
Jun-02-20 09:44AM	Benzinga's Top Upgrades, Downgrades For June 2, 2020 Benzinga
May-27-20 08:00AM	Cortexyme to Present at the Jefferies Virtual Healthcare Conference on June 2, 2020 Business Wire
May-14-20 11:44AM	Are Insiders Buying Cortexyme, Inc. (NASDAQ:CRTX) Stock? Simply Wall St.
May-12-20 04:05PM	Cortexyme Announces First Quarter 2020 Financial Results and Provides Business Update Business Wire
May-07-20 08:00AM	Cortexyme to Present at the BofA Securities 2020 Health Care Conference on May 13, 2020 Business Wire
May-06-20 08:30AM	Cortexyme Publishes Data on P. Gingivalis Ability to Infect Neurons, Drive Alzheimers-Like Pathology in the Journal of Alzheimers Disease Business Wire
Apr-30-20 04:05PM	Cortexyme Appoints Caryn McDowell, J.D. as Chief Legal and Administrative Officer and Corporate Secretary Business Wire
Apr-06-20 08:30AM	Cortexyme to Present at the LifeSci Capital Alpha Series Virtual Conference on April 9, 2020 Business Wire +11.08%
Apr-02-20 08:00AM	Cortexyme Presents Data Supporting Role of P. Gingivalis in Alzheimers Pathology at Advances in Alzheimers and Parkinsons Therapies Virtual Focus Meeting 2020 Business Wire -14.42%
Mar-17-20 08:00AM	Cortexyme Announces Fourth Quarter and Full Year 2019 Financial Results and Provides Business Update Business Wire +17.27%
Mar-16-20 08:00AM	Cortexyme Announces Gain Trial in Alzheimers Disease Has Reached Enrollment Milestone of 300 Patients Business Wire -8.89%
Feb-13-20 08:00AM	Cortexyme Provides Regulatory Update for COR388 Development Program in Alzheimers Disease Business Wire
Feb-10-20 04:05PM	Cortexyme Announces Closing of $125 Million Private Placement Business Wire
Feb-05-20 09:00PM	Cortexyme Announces $125 Million Private Placement Business Wire
Jan-30-20 08:18AM	Cortexyme Announces Publication of New Data Further Demonstrating the Therapeutic Potential of COR388, the Companys Lead Investigational Medicine Business Wire
Jan-13-20 08:00AM	Cortexyme Announces the Initiation of an Open-Label Extension Study for the GAIN Trial of COR388 in Alzheimers Disease Business Wire
Jan-08-20 04:05PM	Cortexyme to Present at the 3rd Annual Neuroscience Innovation Forum on January 12, 2020 Business Wire
Jan-05-20 08:14AM	Here's Why We're Not Too Worried About Cortexyme's (NASDAQ:CRTX) Cash Burn Situation Simply Wall St.
Jan-03-20 10:15AM	Last year's Bay Area IPO performances show why it pays to be an insider American City Business Journals -8.92%
Dec-22-19 06:38PM	Hedge Funds Have Never Been This Bullish On Cortexyme, Inc. (CRTX) Insider Monkey
Dec-13-19 11:16AM	The Zacks Analyst Blog Highlights: Alibaba, Beyond Meat, Cortexyme, Revolve and Uber Zacks +11.00%
Dec-11-19 06:32PM	5 Hottest IPOs of 2019 Zacks
Dec-09-19 08:44AM	Fiverr Languishes Below IPO Price as First Chance to Sell Nears Bloomberg +12.72%
Dec-07-19 01:00PM	Cortexyme Announces Presentation of Data Revealing Link Between Bacterial Pathogen and Genetic Risk for Alzheimers Disease Business Wire
Dec-02-19 01:56PM	Biogen's shares drop on critical view of Alzheimer's data MarketWatch +8.00%
Nov-26-19 04:05PM	Cortexyme to Present at the Evercore ISI 2nd Annual HealthCONx Conference on December 3, 2019 Business Wire
Nov-12-19 04:05PM	Cortexyme Announces Third Quarter 2019 Financial Results and Provides Business Update Business Wire
Nov-08-19 10:34AM	The Zacks Analyst Blog Highlights: Zoom Video Communications, Beyond Meat, Turning Point Therapeutics and Cortexyme Zacks +5.25%
Nov-07-19 08:18AM	4 Best-Performing IPOs So Far in 2019 Zacks +7.99%
Nov-01-19 08:00AM	Cortexyme Announces Oral Presentation on COR388 at Clinical Trials on Alzheimers Disease 2019 Business Wire
Oct-09-19 09:14AM	Top Ranked Momentum Stocks to Buy for October 9th Zacks
Oct-07-19 09:36AM	Did Cortexyme, Inc. (NASDAQ:CRTX) Insiders Buy Up More Shares? Simply Wall St.
Sep-26-19 08:00AM	Cortexyme Announces European Screening Now Underway in the Phase 2/3 GAIN Trial Business Wire
Sep-23-19 10:54AM	Top Ranked Momentum Stocks to Buy for September 23rd Zacks
Aug-08-19 11:45AM	What Percentage Of Cortexyme, Inc. (NASDAQ:CRTX) Shares Do Insiders Own? Simply Wall St. -9.63%
Jul-31-19 04:05PM	Cortexyme to Present at the Canaccord Genuity Growth Conference on August 7th Business Wire
Jul-17-19 11:00AM	Cortexymes Approach to Addressing a Key Underlying Cause of Alzheimers Detailed at Alzheimers Association International Conference 2019 Business Wire
Jul-10-19 08:00AM	Cortexyme Announces Upcoming Data Presentations at the Alzheimers Association International Conference 2019 Business Wire
Jul-05-19 10:05AM	These Bay Area companies are part of an uptick in women-led IPOs American City Business Journals -6.21%
Jul-01-19 02:08PM	Here are big Bay Area winners, losers from busy first half of IPOs American City Business Journals +6.52%
Jun-26-19 12:31PM	Cortexyme's unique approach to Alzheimer's research Yahoo Finance Video

Cortexyme, Inc., a clinical stage biopharmaceutical company, focuses on developing therapeutics for Alzheimer's disease and other degenerative disorders. Its lead drug candidate is atuzaginstat (COR388), an orally administered brain-penetrating small molecule gingipain inhibitor, which is in Phase II/III clinical trial for use in patients with mild to moderate Alzheimer's disease. Cortexyme, Inc. has a partnership with Parkinson Study Group. The company was incorporated in 2012 and is headquartered in South San Francisco, California.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Detke Michael J.	Chief Medical Officer	Jul 07	Option Exercise	2.23	17,400	38,802	17,400	Jul 07 08:38 PM
Detke Michael J.	Chief Medical Officer	Jul 07	Sale	55.20	17,400	960,549	0	Jul 07 08:38 PM
Detke Michael J.	Chief Medical Officer	Jul 06	Option Exercise	2.23	12,600	28,098	40,861	Jul 07 08:38 PM
Detke Michael J.	Chief Medical Officer	Jul 06	Sale	53.54	40,861	2,187,623	0	Jul 07 08:38 PM
McLoughlin Margaret	Director	Jun 28	Sale	55.15	550	30,332	0	Jun 29 05:26 PM
Lynch Casey	Chief Executive Officer	May 10	Sale	34.58	30,000	1,037,361	978,774	May 12 04:51 PM
Lamond David	Director	Mar 24	Buy	33.77	50,000	1,688,500	1,847,109	Mar 24 09:06 PM
Lynch Casey	Chief Executive Officer	Mar 22	Sale	35.59	30,000	1,067,611	1,008,774	Mar 23 07:06 PM
Lamond David	Director	Mar 04	Buy	35.34	50,000	1,767,057	1,797,109	Mar 05 05:54 PM
Lynch Casey	Chief Executive Officer	Feb 03	Sale	43.03	20,000	860,530	1,038,774	Feb 03 07:45 PM
Lynch Casey	Chief Executive Officer	Feb 02	Sale	36.21	20,000	724,102	1,058,774	Feb 03 07:45 PM
Lynch Casey	Chief Executive Officer	Feb 01	Sale	36.25	20,000	724,968	1,078,774	Feb 03 07:45 PM
Holsinger Leslie	Executive Vice President	Dec 14	Option Exercise	0.27	40,000	10,800	43,500	Dec 15 07:17 PM
Holsinger Leslie	Executive Vice President	Dec 14	Sale	30.81	40,000	1,232,528	1,800	Dec 15 07:17 PM
Holsinger Leslie	Executive Vice President	Dec 10	Option Exercise	0.27	3,500	945	3,500	Dec 14 05:16 PM

open in yahoo | open in reuters | open in marketwatch | open in google

Upgrade your FINVIZ experience